Shares of Celgene Corporation (NASDAQ:CELG) ended Thursday session in green amid volatile trading. The shares closed up +0.99 points or 0.90% at $110.57 with 4.46 million shares getting traded. Post opening the session at $110.00, the shares hit an intraday low of $108.54 and an intraday high of $110.85 and the price vacillated in this range throughout the day. The company has a market cap of $86.62 billion and the numbers of outstanding shares have been calculated to be 775.11 million shares.
On September 13, 2016 Celgene Corporation (CELG) and the National Psoriasis Foundation (NPF) have united to mark Wednesday, September 28th as the first-ever Psoriatic Arthritis (PsA) Awareness Day—a day dedicated to raising public awareness around the importance of recognition, diagnosis, and treatment. People are encouraged to join the movement at GoPsADay.com to learn factors associated with PsA, help spread the word via their social channels, and to stand up and be counted for those living with this disease.
More than 1 million Americans live with PsA, although this number may be higher given it is often underreported and misdiagnosed—particularly as symptoms are sometimes confused with other types of arthritis such as rheumatoid arthritis, gout, and reactive arthritis. Some factors associated with PsA include pitted fingernails, swollen fingers and toes, foot pain, joint stiffness and/or pain, and a personal or family history of psoriasis or arthritis.
Early recognition, diagnosis, and treatment of psoriatic arthritis is critical for anyone living with the disease. Those who are experiencing any of the common symptoms of PsA should contact their healthcare provider.
“Psoriatic arthritis can present significant challenges to those living with the disease, including significant pain and swelling in joints that may impact a person’s activities of daily living,” said Madelaine Feldman, MD, rheumatologist. “While there is no cure, PsA can be managed, which is why it is critical for people to know the factors associated with PsA, talk with their healthcare provider to obtain the right diagnosis, and determine a treatment plan that works for them.”
Shares of Medtronic PLC (NYSE:MDT) ended Thursday session in green amid volatile trading. The shares closed up +0.68 points or 0.78% at $87.82 with 4.35 million shares getting traded. Post opening the session at $87.52, the shares hit an intraday low of $87.40 and an intraday high of $88.04 and the price vacillated in this range throughout the day. The company has a market cap of $121.36 billion and the numbers of outstanding shares have been calculated to be 1.38 billion shares.
Medtronic PLC (MDT) on Sept. 20, 2016 announced new data, demonstrating safety and efficacy at three years in acute complicated Type B aortic dissection patients treated with the Valiant® Captivia® Thoracic Stent Graft System. Ali Azizzadeh, MD, FACS, University of Texas Health Science Center in Texas presented the new clinical data in a late-breaking trial session at Vascular Interventional Advances (VIVA) 2016.
An acute aortic dissection is a serious condition in which the inner layer of the aorta tears, blood surges through the tear, and causes the inner and middle layers of the aorta to separate. This can result in aorta rupture or malperfusion of the vessels originating from the dissected aorta, leading to high morbidity and mortality. A type B dissection is a tear located in the descending aorta.
“Evidence shows that patients with acute complicated Type B aortic dissections can be safely and effectively treated with thoracic endovascular aortic repair (TEVAR),” said Dr. Azizzadeh. “The Valiant Captivia System continues to produce positive outcomes through three years in a very challenging patient population.”